These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27910150)

  • 1. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
    Whitehead WE; Duffy K; Sharpe J; Nabata T; Bruce M
    Aliment Pharmacol Ther; 2017 Jan; 45(1):14-26. PubMed ID: 27910150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
    Gunn D; Fried R; Lalani R; Farrin A; Holloway I; Morris T; Olivier C; Kearns R; Corsetti M; Scott M; Farmer A; Emmanuel A; Whorwell P; Yiannakou Y; Sanders D; Mclaughlin J; Kapur K; Eugenicos M; Akbar A; Trudgill N; Houghton L; Dinning PG; Ford AC; Aziz Q; Spiller R
    Trials; 2019 Aug; 20(1):517. PubMed ID: 31429811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
    Tack JF; Miner PB; Fischer L; Harris MS
    Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.
    Chmielewska-Wilkoń D; Reggiardo G; Egan CG
    World J Gastroenterol; 2014 Sep; 20(34):12283-91. PubMed ID: 25232263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.
    Trifan A; Burta O; Tiuca N; Petrisor DC; Lenghel A; Santos J
    United European Gastroenterol J; 2019 Oct; 7(8):1093-1101. PubMed ID: 31662866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.
    Saito YA; Almazar AE; Tilkes KE; Choung RS; Van Norstrand MD; Schleck CD; Zinsmeister AR; Talley NJ
    Aliment Pharmacol Ther; 2019 Feb; 49(4):389-397. PubMed ID: 30663077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea.
    Lembo A; Kuo B; Boinpally R; Li E; Mallick M; Bochenek W; Bartolini W
    Aliment Pharmacol Ther; 2023 Jan; 57(2):192-204. PubMed ID: 36324245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
    Howell CA; Kemppinen A; Allgar V; Dodd M; Knowles CH; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Gut; 2022 Dec; 71(12):2430-2438. PubMed ID: 35760493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome.
    Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
    Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
    Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
    Plasse TF; Barton G; Davidson E; Abramson D; Kalfus I; Fathi R; Raday G; Harris MS
    Am J Gastroenterol; 2020 Sep; 115(9):1466-1473. PubMed ID: 32639235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translocator protein 18kDa antagonist ameliorates stress-induced stool abnormality and abdominal pain in rodent stress models.
    Kawahara Y; Mitsui K; Niwa T; Morimoto N; Kawaharada S; Katsumata S
    Neurogastroenterol Motil; 2018 Nov; 30(11):e13425. PubMed ID: 30069991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleotide supplementation: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome [ISRCTN67764449].
    Dancey CP; Attree EA; Brown KF
    Nutr J; 2006 Jun; 5():16. PubMed ID: 16762076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Chen C; Tao C; Liu Z; Lu M; Pan Q; Zheng L; Li Q; Song Z; Fichna J
    Phytother Res; 2015 Nov; 29(11):1822-7. PubMed ID: 26400188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.